Iovance Biotherapeutics, Inc. demonstrates improved Q4 results, with $87M revenue and a 50% gross margin. Learn more about IOVA stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results